Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72632 record(s)

Req # A-2021-001530

Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: 000935818, 000938303.

Organization: Health Canada

13 page(s)
July 2024

Req # A-2022-000323

Adverse Drug Reactions (ADRs) for Invanz. Report numbers: E2B_02980169, E2B_02688263, E2B_03106484, E2B_02727599, E2B_02897744, E2B_02802085, E2B_03260531, 000911379, 000737908, 000728027.

Organization: Health Canada

622 page(s)
July 2024

Req # A-2022-001201

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-011904-710, Meet and Greet with Chair of the Board of Directors, Coalition for Epidemic Preparedness Innovations.

Organization: Health Canada

8 page(s)
July 2024

Req # A-2022-001461

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-113702-970.

Organization: Health Canada

5 page(s)
July 2024

Req # A-2023-000056

Adverse Drug Reactions (ADRs) for TEMODAL. Report numbers: E2B_02972534, E2B_02052614, E2B_02052639, E2B_02589651, E2B_02980971, E2B_03071012, 000908947, E2B_03593802.

Organization: Health Canada

104 page(s)
July 2024

Req # A-2023-000086

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-101001-49.

Organization: Health Canada

59 page(s)
July 2024

Req # A-2023-000090

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-101662-145.

Organization: Health Canada

12 page(s)
July 2024

Req # A-2023-000319

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-102100-548.

Organization: Health Canada

166 page(s)
July 2024

Req # A-2023-000920

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-108006-824.

Organization: Health Canada

28 page(s)
July 2024

Req # A-2023-001133

Adverse Drug Reactions (ADRs) for Morphine. Report numbers: 001056184, E2B_00463532, E2B_008003504, 001056381, 001064525. ADR for Heparin. Report number: E2B_06634659. ADRs for Midazolam. Report numbers: 001055123, 001056693, 001060809.

Organization: Health Canada

2013 page(s)
July 2024
Date modified: